Scholarlink

<p>Augmentation therapy is a treatment option available in the market that has been approved by the U.S. Food and Drug Administration (FDA) for alpha-1-antitrypsin (A1AT) deficient patients. The treatment requires weekly injections of purified A1AT for the patients and relies on plasma donor. The demand for A1AT is also high due to its functional role in various diseases. However, scaling up production of purified human plasma A1AT remained costly and challenging. It is therefore of great interest to generate A1AT at larger scale in ensuring a consistent supply to the market. In this paper, we evaluated the stability and productivity of ten Chinese Hamster Ovary (CHO) single cell clones over 12&#xa0;weeks. This was followed by scaling up the fed-batch production of A1AT with the selected cell clone in a 10L single-use surface aerated orbital shaken bioreactor SB10-X. The cell specific productivity of the two bioreactor runs were at 9.6 and 12&#xa0;pg/cell/day (pcd) respectively, which were comparable to shake flasks. While the paper focuses on the possibility to scale up A1AT production, process conditions such as feeding regime could be investigated to further prolong the culture longevity and increase productivity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Scaled up fed-batch production of recombinant alpha-1-antitrypsin by CHO cells in single-use surface aerated orbital shaken bioreactor

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月8日

查看全文
  • Wen Qin Tang,
  • Chloe Qiu Zhen Jiang,
  • Zi Ying Zheng,
  • Ally Lau,
  • Xuezhi Bi,
  • Wei Zhang,
  • Say Kong Ng

摘要

Augmentation therapy is a treatment option available in the market that has been approved by the U.S. Food and Drug Administration (FDA) for alpha-1-antitrypsin (A1AT) deficient patients. The treatment requires weekly injections of purified A1AT for the patients and relies on plasma donor. The demand for A1AT is also high due to its functional role in various diseases. However, scaling up production of purified human plasma A1AT remained costly and challenging. It is therefore of great interest to generate A1AT at larger scale in ensuring a consistent supply to the market. In this paper, we evaluated the stability and productivity of ten Chinese Hamster Ovary (CHO) single cell clones over 12 weeks. This was followed by scaling up the fed-batch production of A1AT with the selected cell clone in a 10L single-use surface aerated orbital shaken bioreactor SB10-X. The cell specific productivity of the two bioreactor runs were at 9.6 and 12 pg/cell/day (pcd) respectively, which were comparable to shake flasks. While the paper focuses on the possibility to scale up A1AT production, process conditions such as feeding regime could be investigated to further prolong the culture longevity and increase productivity.